The Government of Québec announced today an investment in the Personalized Medicine Partnership for Cancer (PMPC). The PMPC will be under the leadership of Caprion Proteome Inc., a Montreal-based biotech company specializing in the discovery and development of protein-based diagnostic biomarkers.
Génome Québec congratulates Martin LeBlanc, President and Chief Executive Officer of Caprion Proteomics, who is the head of this public-private partnership with a total value of $ 21.1 million.
For more information, click here.